4Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin, 2005, 55:74-108.
5Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353 : 123-132.
6Bezjak A, Tu D, Seynour L, et al. Symptom improvement in lung cancer patients treated with erlotinib : quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol, 2006, 24:3831-3837.
7Groen H, Arrieta OG, Riska H, et al. The global TRUST study of erlotinib in advanced non-small-cell lung cancer(NSCLC). J Clin Oncol, 2008, 26 :abstr19000.
8Mok TS, Zhou C, Kim S, et al. Efficacy and safety of erlotinib in > 1200 East/South-East(E/SE) Asian patients(pts) with advanced non-small-cell lung cancer(NSCLC). J Clin Oncol, 2008, 26: abstr 19001.
9Clark GM, Zborowski DM, Santabatrbara P, et al. Smoking history and epideramal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. Clin Lung Cancer, 2006, 7:389-394.
10Clark GM. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oneol, 2008, 91:406-412.
